AstraZeneca (AZN LN) CEO says we do not need new deals in weight loss, drug prices in the US will come down but Europe's must rise
Context
AstraZeneca's CEO indication that the company doesn't seek new deals in weight loss signals confidence in their current pipeline and strategic focus. The comments on drug prices suggest a strategic pivot for the U.S. market while contrasting with the need for higher prices in Europe, potentially impacting AstraZeneca's competitive positioning and profitability across regions.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#ASTRAZENECA PLC#AZN.LN#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#FTSE 100